Shares of Merck KGaA (OTCMKTS:MKGAY – Get Rating) have earned an average rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $252.50.
MKGAY has been the topic of a number of recent research reports. UBS Group raised Merck KGaA from a “sell” rating to a “neutral” rating in a report on Monday, February 28th. JPMorgan Chase & Co. lowered their price objective on Merck KGaA from €270.00 ($287.23) to €250.00 ($265.96) and set an “overweight” rating for the company in a research note on Monday, March 14th.
Shares of MKGAY remained flat at $$38.36 during trading hours on Friday. Merck KGaA has a 1 year low of $32.53 and a 1 year high of $42.02. The company’s 50-day moving average is $38.36 and its two-hundred day moving average is $38.36.
Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.
- Get a free copy of the StockNews.com research report on Merck KGaA (MKGAY)
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- It’s Time to Buy into Planet Fitness Stock
- Indie Semiconductor Stock is Putting in a Bottom
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.